 |
|
| Dear %%Firstname%%, |
|
| Antibody Drug Conjugates (ADCs) have evolved since the initial approval of MYLOTARG® in 2000 with respect to conjugation, linker and toxin chemistries and processing. With the current availability of four commercially approved drugs and approximately 80 programs in various clinical trials, there has been a significant interest in simplifying the complex supply chain. With approximately 80% of the programs outsourced to Contract Development and Manufacturing Organizations (CDMOs), a transparent and integrated supply chain is critical for the success of ADC projects. |
|
| In this White Paper, you will learn more about:
|
|
| • |
How ADC manufacturing has evolved over the past decade |
|
| • |
The challenges that this evolution implies |
|
| • |
Why an integrated supply chain has become increasingly important for the success of ADC projects |
|
|
|
|
|
|
 |
|
| Merck offers a comprehensive portfolio of products and services for ADC manufacturing. If you would like to learn more, click here |
|
|
|
|
|
